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Abstract
Introduction: Management of osteoarthritis (OA) includes the use of non-pharmacological and pharmacological
therapies. Although walking is commonly recommended for reducing pain and increasing physical function in
people with OA, glucosamine sulphate has also been used to alleviate pain and slow the progression of OA. This
study evaluated the effects of a progressive walking program and glucosamine sulphate intake on OA symptoms
and physical activity participation in people with mild to moderate hip or knee OA.
Methods: Thirty-six low active participants (aged 42 to 73 years) were provided with 1500 mg glucosamine
sulphate per day for 6 weeks, after which they began a 12-week progressive walking program, while continuing to
take glucosamine. They were randomized to walk 3 or 5 days per week and given a pedometer to monitor step
counts. For both groups, step level of walking was gradually increased to 3000 steps/day during the first 6 weeks
of walking, and to 6000 steps/day for the next 6 weeks. Primary outcomes included physical activity levels, physical
function (self-paced step test), and the WOMAC Osteoarthritis Index for pain, stiffness and physical function.
Assessments were conducted at baseline and at 6-, 12-, 18-, and 24-week follow-ups. The Mann Whitney Test was
used to examine differences in outcome measures between groups at each assessment, and the Wilcoxon Signed
Ranks Test was used to examine differences in outcome measures between assessments.
Results: During the first 6 weeks of the study (glucosamine supplementation only), physical activity levels, physical
function, and total WOMAC scores improved (P < 0.05). Between the start of the walking program (Week 6) and the
final follow-up (Week 24), further improvements were seen in these outcomes (P < 0.05) although most improvements
were seen between Weeks 6 and 12. No significant differences were found between walking groups.
Conclusions: In people with hip or knee OA, walking a minimum of 3000 steps (~30 minutes), at least 3 days/
week, in combination with glucosamine sulphate, may reduce OA symptoms. A more robust study with a larger
sample is needed to support these preliminary findings.
Trial Registration: Australian Clinical Trials Registry ACTRN012607000159459.
Introduction
Osteoarthritis (OA) is the most common musculoskele-
tal disorder and the leading cause of pain and disability
in the USA and Australia [1,2]. In Australia, it affects
7.8% of the population, and projections indicate that the
prevalence will increase to 9.8% by 2020 [3].
There is no known cure for OA. The goal of treat-
ment, therefore, is to help reduce patients’ pain, prevent
reductions in their functional ability and maintain or
increase their joint mobility. For individuals with moder-
ate symptoms of OA and no other health problems,
international guidelines for initial treatment recommend
non-pharmacological treatments, including lifestyle
changes [4-9]. A number of non-pharmacological treat-
ments have been studied for the management of OA,
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the effectiveness of most non-pharmacological treat-
ments is open to question [10].
Exercise, however, as a treatment for OA has been
s t u d i e di nn u m e r o u sr a n d o m i s e dc o n t r o l l e dt r i a l s ,
mostly in people with OA of the knee. Most of these
have focused on improving the stability of joints, range
of movement and aerobic fitness in order to decrease
patients’ pain and disability [11]. Patients with mild to
moderate symptoms of knee or hip OA who have parti-
cipated in aerobic exercise programs have experienced
increases in aerobic capacity [11,12] and functional abil-
ity [13,14], and decreases in pain, fatigue, depression
and anxiety [11-13,15]. These results have led to recom-
mendations for the use of aerobic exercise for the treat-
ment of OA [4,7-9].
A recent review of randomised controlled trials in
patients with knee OA found three types of exercise
program (supervised individual, supervised group-based
and unsupervised home-based) have been evaluated,
with decreases in pain and physical function not differ-
ing significantly among participants in the three types
[13]. In contrast to pharmacological treatments, which
can cause gastrointestinal side effects [16], moderate-
intensity aerobic exercises are well tolerated over the
long term and have similar effects (effect size [ES] =
0.52) [17] for reducing pain to those seen with paraceta-
mol and nonsteroidal anti-inflammatory drugs (NSAIDs;
ES = 0.32) [18]. Compared with supervised programs,
home-based programs are more convenient for partici-
pants, feasible in community settings and cost-effective
for large populations, suggesting their suitability as a
public health approach [13].
Walking may be an appropriate activity for home-
based programs [19], because it has resulted in greater
improvements in pain and greater participation rates
than other forms of aerobic exercise, such as running or
cycling [20]. In studies assessing the effectiveness of
walking for patients with knee OA, moderate improve-
ments in pain (ES = 0.52) and physical functioning
(ES = 0.32) have been found [17] without adverse effects
on OA symptoms [14]. The Physical Activity Guidelines
Advisory Committee recommends that individuals with
OA engage in moderate-intensity, low-impact activities
such as walking, three to five times per week for 30 to
60 minutes per session [21].
Despite the accumulating international evidence sug-
gesting that aerobic exercise is effective in reducing
symptoms of OA of the knee, and to a lesser degree of
the hip, an important question remains: What is the
appropriate ‘dose’ of exercise (intensity, frequency, and
duration) for significant improvements in symptoms of
knee and hip OA? More broadly, the question of an
appropriate dose of exercise has yet to be determined
for people with arthritis in general [21]. In previous stu-
dies, exercise format, duration, intensity, and type of
exercise varied widely, making it difficult to specify the
required dose for optimal benefits. Even among the stu-
dies that used walking, programs have varied in content,
duration of sessions and length of the intervention [17].
Only one small study [22] has examined the dose issue,
and it focused on intensity of exercise. The researchers
found that higher and lower intensity exercises are
equally effective in improving symptoms of OA.
One treatment that is used in combination with or
without exercise by some people with early hip or knee
OA is glucosamine sulphate (GS), a natural occurring
substance believed to assist with building and repair of
cartilage. It is taken as a complementary medicine that
is safe and has few side effects [8]. Two recent rando-
mised trials from Europe have shown that GS slows
radiological progression of knee OA [23,24]. In a meta-
analysis of 20 double-blind randomised control trials,
glucosamine was reported to improve well-being and to
be as safe as placebo [25]. Although results of a review
further suggest glucosamine offers moderate improve-
ments in well-being [26], some trials reported little or
non-significant effects of glucosamine when compared
with placebo [27,28]. These conflicting results could be
due to differences in the type of preparation used (GS
or glucosamine hydrochloride), dose or bioavailability of
the glucosamine preparation used.
Although some individuals with OA are using both glu-
cosamine and exercise to relieve symptoms, no study has
examined the effectiveness of the combined effects of
exercise and GS on relieving symptoms of hip and knee
OA. The main aim of this feasibility study was to evaluate
the combined effects of a progressive walking program
and GS intake on symptoms of OA and physical activity
participation in people with hip or knee OA. Secondary
aims were to compare the effectiveness of two frequen-
cies of walking (three and five days per week) and three
step levels (1500, 3000 and 6000 steps per day) of walk-
ing, combined with GS intake, and to examine compli-
ance with GS intake and the walking program.
Materials and methods
Participants
Adults with hip or knee OA were recruited in Brisbane,
Australia, from flyers posted at community sites and in
doctors’ offices, newspaper and newsletter advertise-
ments, and segments on local television and radio pro-
grams. Eligibility criteria were: aged 40 to 75 years;
having physician-diagnosed OA in at least one hip or
knee (verified by a doctor’sl e t t e rc o n f i r m i n gd i a g n o s i s ) ;
experiencing pain, stiffness, crepitus and difficulty with
daily activities within the previous month; an ability to
walk at least 15 minutes continuously; and an ability to
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determined by the Sports Medicine Australia Stage I
pre-exercise screening questions [29]. Individuals were
excluded if they: had other forms of arthritis; had corti-
costeroid or viscosupplement injections within the pre-
vious three months; had a history of infection in a knee
or hip; were living in a dependent environment; were
taking daily medication for OA, including analgesia; or
were allergic to shellfish. Individuals who were planning
to have surgery in the next six months, receiving psy-
chiatric or psychological treatment, pregnant or plan-
ning to become pregnant, exercising more than 60
minutes per week, or participating in another research
study were also excluded.
Study design
T h es t u d yd e s i g ni ss h o w ni nF i g u r e1 .T h i sw a sa2 4 -
week feasibility study with participants randomised to
one of two intervention groups. Written informed con-
sent was required at the baseline assessment, before
participation could begin. Participants went through a
two-week run-in, washout period before the first assess-
ment. For this period and the rest of the study period,
participants were informed to discontinue all over-the-
counter or prescription medications for their OA symp-
toms. However, they were told that they could take their
choice of rescue analgesia as needed for pain or swelling
during the study period.
Before the first assessment, the data collector (author
NTMN) used a computer random number generator to
allocate participants to one of two groups. Participants
were told of their group allocation at the baseline
assessment. For practical reasons, allocation to group
was not concealed. All participants received six-week
supplies of GS at baseline, Week 6 and Week 12. At
Week 6, participants began a 12-week progressive walk-
ing program called Stepping Out, either walking three
or five days per week, depending on group assignment.
The walking program ended at Week 18. The next six
weeks constituted a follow-up period to test whether the
intervention effects persisted after intervention comple-
tion. Study measures were administered during one-on-
one interviews with participants at baseline and 6-, 12-,
18-, and 24-weeks after baseline. Assessments were con-
ducted at the University of Queensland or at the partici-
pant’s home. The study protocol was approved by the
University of Queensland Medical Research Ethics
Committee.
Main outcome measures
Physical activity Time spent in physical activities was
measured using a print version of the Active Australia
physical activity questions [30], which have been shown
to have acceptable reliability and validity [31]. A com-
parison of activity classification (i.e. ‘active,’‘ insuffi-
ciently active,’‘ sedentary’) showed moderate agreement
between two testing occasions, 24 hours apart (Kappa
coefficient = 0.50), a finding similar to those observed
for other physical activity questionnaires used interna-
tionally [32]. Walking (to and from places and for exer-
cise), leisure-time moderate-intensity physical activities,
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separately. Minutes per week spent in each of these
activities was summed to create a total physical activity
score.
Osteoarthritis symptoms The Western Ontario and
McMaster Universities (WOMAC) Osteoarthritis Index
numeric rating scale (NRS) 3.1 was used to measure
pain, stiffness and physical function [33]. The index has
been extensively validated and widely used in studies of
knee and hip OA [34,35]. The index consists of three
subscales with a total of 24 items (5 pain, 2 stiffness and
17 physical function) with test-retest reliability estimates
of 0.68, 0.68 and 0.72 for the pain, stiffness, and physical
function subscales, respectively [34,35]. Participants
placed an ‘x’ on a numerical (visual analogue) scale ran-
ging from 0 to 10. For the pain subscale, response
options ranged from no pain to extreme pain; for the
stiffness subscale, from no stiffness to extreme stiffness;
and for the physical function subscale, from no difficulty
to extreme difficulty. Responses to items on each of the
three subscales were summed to create subscale scores.
A total scale score (range 0 to 240) was calculated by
simple summation of these subscale scores with higher
scores indicating more severe symptoms.
Physical function was also assessed objectively with
the Self-Paced Step Test (SPS) [36]. This test was
selected because it could be used in participants’ homes:
it was portable, practical for use with minimal space and
suitable for use in individuals with OA. Participants
were asked to step up and down two 20 cm steps, 20
times at a comfortable pace. Time taken to complete
the test was recorded to the nearest second with a digi-
tal stopwatch. A higher score indicated lower physical
function. Immediately after the SPS test, the WOMAC
pain subscale was re-administered to assess the level of
pain after an activity that involved movement of the hip
and knee joints.
Secondary outcome measures
Correlates of physical activity Five theoretical con-
structs that were addressed in the Stepping Out pro-
gram were measured with questionnaires. The Arthritis
Self-Efficacy Scale assessed confidence of affecting
change for managing arthritis pain, function and other
symptoms, with higher scores indicating greater efficacy
for managing symptoms [37]. One study has demon-
strated adequate internal consistency for the scale’s pain
(Cronbach alpha = 0.76), function (Cronbach alpha =
0.89) and other symptoms (Cronbach alpha = 0.87) sub-
scales [37]. The Self-Regulation Scale assessed the use of
self-monitoring and goal setting strategies for physical
activity behaviour with higher scores representing higher
self-efficacy in meeting physical activity goals. Higher
self-regulation scores have been associated with enga-
ging in more moderate and vigorous physical activities
(r = 0.50) [38]. The Self-Efficacy for Physical Activity
Scale evaluated confidence in ability to participate regu-
larly in physical activities, with higher scores indicating
greater self-efficacy for physical activity. A high test-ret-
est reliability estimate (r = 0.90) has been reported for
this scale [39]. The Benefits of Physical Activity Scale
determined whether participants were aware of the ben-
efits of physical activity, and the Barriers to Physical
Activity Scale identified factors that made participation
in physical activities difficult [40]. Higher scores on the
Benefits of Physical Activity Scale indicated a perception
of more benefits, and a high test-retest reliability (r =
0.85) has been reported for this scale [40]. Higher scores
on the Barriers to Physical Activity Scale indicated a
perception of more barriers to physical activity. Barrier
scale scores have been significantly and inversely corre-
lated with exercise (r = -0.22) [40].
Health outcomes
The Goldberg Anxiety and Depression Scale [41] was
used to measure symptoms of anxiety and depression.
Nine items measured anxiety, and an additional nine
measured depression, with response options of ‘Yes’ and
‘No’. The summary score was calculated by adding the
total number of ‘Yes’ responses to the 18 items. With a
range of 0 to 18 on the scale, a higher score indicated
more symptoms of anxiety and depression. The anxiety
and depression subscales have sensitivities of 82% and
85%, respectively.
Body weight was measured to the nearest 0.5 kg using
calibrated portable scales (SECA, Hamburg, Germany).
Demographic characteristics
Data on age, country of birth (a measure of race/ethni-
city), marital status, living arrangements, caring respon-
sibilities, education and employment status were
collected using a self-report survey.
The intervention
Starting at baseline, participants were supplied with GS
(Bio-Organics™ Glucosamine Sulphate Complex 1000,
Virginia, Queensland, Australia) and asked to take two
capsules (750 mg each) daily. The Stepping Out pro-
gram commenced at Week 6. It was developed to influ-
ence self-efficacy (confidence in one’s ability to be
physically active) and other constructs from Social Cog-
nitive Theory that were hypothesised to impact self-effi-
cacy [42]. This theory has been found to be effective as
a framework for previous interventions in which OA
sufferers managed their OA with exercise [43-48].
The Stepping Out program included: a walking guide;
a pedometer; weekly log sheets for recording daily step
counts, GS intake and intake of other medications and
supplements; and a weekly planner for scheduling walk-
ing sessions (Table 1). Participants were encouraged to
use strategies from the Stepping Out walking guide, to
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included behavioural contracting (using a written con-
tract to meet the study requirements), goal setting, plan-
ning for walking sessions, and obtaining social support
for walking. The interventionists also brainstormed with
participants ways to increase their walking, make their
walks enjoyable and overcome barriers to walking. This
interaction with the interventionist lasted approximately
one hour. Details of the content of each strategy can be
found in Table 1. All participants received the same
materials and instructions, but participants in the three-
day walking group were asked to walk three days per
week and participants in the five-day walking group
were asked to walk five days per week.
Participants received the program materials and
instructions for following the program and wearing the
pedometer after the assessment portion of the Week 6
session. The first author (NTMN, a doctoral student
with training in exercise science and physical activity
behaviour change) served as both data collector and
interventionist. At that session, participants were asked
to initially walk at least 1500 steps (approximately 15
minutes) on each ‘walking’ day in addition to any walk-
ing they were currently doing, and to do this additional
walking in a single session. They were asked to increase
from 1500 steps to 3000 steps (approximately 30 min-
utes) by the Week 12 assessment and, to accommodate
participants who were unable to walk this amount con-
tinuously, were advised that the walks could be done in
bouts of at least 1500 steps each. They were also advised
to increase their step counts at a rate that was comforta-
ble for them. At the Week 12 session, participants were
asked to increase their walking to 6000 steps (approxi-
mately 60 minutes) by Week 18, the end of the inter-
vention. At the Week 18 session, they were advised to
either continue with the walking program or to try
Table 1 Stepping Out program topics and the theoretical constructs addressed by each one
Mode of delivery
a Topic Content Constructs
addressed
Walking guide;
one-on-one
consultations
Provide opportunities and social
support; correct misperceptions
Provide tips on finding opportunities in the environment for
walking;
Discuss barriers to doing the program and ways to
overcome them in the future;
Discuss walking as an activity readily available (e.g., can walk
anyway, inexpensive);
Suggest that friends or family be asked to provide
encouragement and support for doing the program.
Environment
Walking guide;
one-on-one
consultations
Provide opportunities for experiencing benefits
and learning what to expect from changing
behaviour
Address health benefits of walking and other physical
activities for OA sufferers;
Explain normal bodily responses to starting a walking
program;
Provide warning signs of excessive exercise.
Outcome
expectations
Walking guide Rewarding for behaviour change Discuss positive impact of walking on OA symptoms;
Describe physiological benefits of walking as rewards for
increasing walking behaviour.
Reinforcement
Walking guide; one-
one-one
consultations
Behavioural capability
Mastery learning
Observational learning
Discuss and demonstrate proper walking techniques
pertaining to posture, arm motion, taking a step, walking
stride, and pace;
Discuss ‘safe’ walking;
Advice on selecting walking shoes;
Discuss the use of short bouts (1500 steps) of walking to
improve health and OA symptoms;
Instruct to increase steps at own rate;
Display stretching exercises.
Self-efficacy
Walking guide;
pedometer;
log sheets;
weekly planners;
one-one
consultations
Self-regulation and
self-monitoring
Provide use of a pedometer for 12 weeks;
Advice on and review of setting step goals;
Guide in writing weekly step goals on log sheet and
request a copy be sent to researchers weekly;
Guide in monitoring step counts of each program walk with
log sheet and request a copy be sent to researchers weekly.
Guide in planning walks (specifying time, place and steps to
walk) using a weekly planner.
Self-control
Walking guide; one-
on-one
consultations
Self-talk Provide techniques for replacing negative self-statements
with positive ones.
Emotional-
coping
responses
aThe Walking Guide was a 27-page booklet developed for the Stepping Out program. The Walking Guide, a pedometer, log books, and weekly planners were
distributed at the Week 6 session. One-on-one consultations occurred immediately following the assessments at Weeks 6, 12, and 24.
OA = osteoarthritis.
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weeks of the study, the follow-up period.
Statistical analysis
Study completers were compared with those who
dropped out of the study, using demographic and out-
come variables measured at baseline. Likewise, the
three-day and five-day walking groups were compared at
baseline. Categorical variables were examined using the
chi-squared test for independence, and continuous vari-
ables were examined with the Mann Whitney test,
because the data were not normally distributed. For the
Mann Whitney test, differences in the ranked positions
of scores in different groups are compared [49].
Compliance with the study protocol’s recommendation
for GS intake, for the number of ‘walking’ days per
week, and for the number of steps to walk each ‘walking
day’ were computed using data collected from weekly
log sheets. For each week between baseline and Week
18, GS compliance was defined as the proportion of par-
ticipants who recorded taking two GS capsules per day
at least five days of the week. For each week between
Weeks 6 and 18, compliance with the number of walk-
ing days was defined as the proportion of participant
who reported walking the prescribed number of days
(three for the three-day walking group; five for the five-
day walking group). Compliance with the number of
steps prescribed for each walking day was defined as the
proportion of participants who reported walking 1500
steps at Week 7 (after the first week of walking), 3000
steps at Week 12 and 6000 steps at Week 18. Chi-
squared test for independence was used to compare
groups on the proportion of participants who complied
with the recommendation for GS intake each week.
Independent samples t-tests were used to compare
groups on the mean number of days walked during each
of the 12 weeks of the Stepping Out program and on
the mean number of steps walked per ‘walking’ day dur-
ing that time. Type and usage of rescue analgesia were
also collected from weekly log sheets, and median num-
ber of days that these medications were used over the
intervention period was computed.
The Mann Whitney test was used to examine differ-
ences between the three-day and five-day walking
groups at Weeks 6, 12, 18 and 24 for the main outcome
variables, physical activity and OA symptoms. The
remaining analyses were then analysed separately by
group, only if group differences were found. Otherwise,
data from the two groups were pooled for analysis of
intervention effects. Differences between assessment
weeks in scores on all outcome variables were examined
using the Wilcoxon Signed Ranks Test. An effect size (r;
z-score divided by the square root of the sample size)
was computed for each statistically significant finding
[49], and Cohen’s d benchmark was used to determine
the magnitude of the effect, with 0.20 representing
small, 0.50 representing moderate and 0.80 representing
large effect sizes [50]. Confidence intervals for the effect
sizes were not calculated because data were not nor-
mally distributed. Instead, inter-quartile ranges of the
raw scores were computed. Given that this was a feasi-
bility study, data were analysed on a per protocol basis,
meaning that participants who did not complete all
study assessments were excluded. For study completers,
missing data were replaced by the mean of the preced-
ing and proceeding values [51]. Statistical significance
was set at a two-tailed alpha level of 0.05 for all
analyses.
Results
Participants
Over 16 weeks of recruitment, 536 people expressed
interest in the study (Figure 2). The preliminary screen-
ing revealed that 48% had physician-diagnosed OA in a
knee or hip. Of these, 14% met all eligibility criteria,
gave written informed consent and were enrolled into
the study. Of those who met the eligibility criteria, 47%
(n = 17) were randomised to the five-day walking group
and 53% (n = 19) to the three-day walking group. Of
the participants who enrolled, 77% completed the study
(three-day group: n = 13, five-day group: n = 15). Three
participants dropped out during the first six weeks of
the study, before the walking program began. Reasons
were a death in the family (n = 1), a physician’sa d v i c e
to withdraw due to potential impact of walking on OA
(n = 1) and a physician’s advice to withdraw due to
potential impact of walking on other health conditions
(n = 1). Five additional participants dropped out during
the walking program. Reasons for drop-out from the
three-day walking group were a death in the family (n =
1; dropout in Week 8), pain in the knees (n = 1; Week
7) and a torn Achilles tendon (n = 1; Week 7), and
from the five-day walking groups were pain while walk-
ing due to leg length discrepancies (n = 1; Week 12)
and development of Bakers’ Cyst causing pain while
walking (n = 1; Week 9). None of these conditions was
directly attributable to participation in the program. No
differences were found between study completers and
those who dropped out on any study variable.
Demographic characteristics of study completers are
presented in Table 2. Intervention groups did not differ
significantly on any of the variables examined.
Compliance
From baseline to Week 18, 100% of three-day group
participants were compliant with taking the weekly GS
supplementation for all but three weeks, and 100% of
five-day group participants were compliant with taking
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For weeks in which compliance was not 100%, compli-
ance was 90% or more for each intervention group. No
differences were found between groups in the propor-
tion who were compliant with taking the GS (P = 0.18).
Nineteen of the 28 study participants (three-day group
n = 7, 58%, five-day group n = 12, 80%) reported taking
paracetamol and/or NSAIDs as rescue analgesia, with the
most popular medications being paracetamol prepara-
tions (n = 12). Over the 18-week intervention period,
study participants took rescue analgesia a median of 5.5
days (25
th percentile = 0 days; 75
th percentile = 18 days).
For each week of the Stepping Out program (Weeks 7
to 18), most participants in both groups were compliant
with walking the number of ‘walking days’ called for in
the protocol (i.e., they walked the prescribed three or
five days per week), but compliance was higher in the
three-day walking group than in the five-day walking
group (Figure 3). Among participants in the three-day
walking group, there was 100% compliance with walking
three days per week during Weeks 8, 9, 12, 15, and 18.
Among participants in the five-day walking group, com-
pliance ranged from 93% (Week 7) to 58% (Week 16)
during the 12-week walking program. The mean num-
ber of days walked throughout the 12 weeks was also
computed. No significant difference in number of days
walked were found between groups although there was
a trend in significance (P =0 . 0 6 ) .O na v e r a g e ,p a r t i c i -
pants in the three-day group walked three days per
week (mean days/week = 3.07 (standard deviation (SD)
0.82) days), but participants in the five-day group did
not walk five days per week (mean days/week = 3.93
(SD 1.09) days).
Another measure of compliance was the proportion of
participants in each group who complied with the num-
ber of steps indicated in the study protocol. In the first
week of the walking program (Week 7), 89% of partici-
pants in the three-day group and 93% in the five-day
536 expressed interest in the feasibility study 
279 (52%)  
Ineligible after initial screening 
 Did not have OA 
36 (14%)  
Met eligibility criteria and randomised 
28 (77%) 
Completed study 
221 (86%)  
Did not meet eligibility criteria 
 Doing > 60 mins of PA per week 
 Taking pain  relief medication  
 Unable to commit to study 
257 (48%)  
Eligible for further screening 
8 (23%) 
Did not complete study 
6 (17%) - health reasons 
1 (3%) - personal reasons 
1 (3%) - daily pain medication 
19 (53%) 
3-day walking group 
17 (47%) 
5-day walking group  
Figure 2 Process of recruitment for the study. OA, osteoarthritis. PA, physical activity.
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walking day. These percentages decreased to 75% in the
three-day group and 79% in the five-day group by Week
12 when the target step level increased to 3000 steps. By
Week 18, when the target step level increased to 6000
steps, the percentages were 83% and 50% in the three-
and five-day groups, respectively. Participants in both
groups increased the number of steps they walked each
‘walking’ day over the weeks of the Stepping Out pro-
gram, and no significant group differences in steps per
‘walking’ day were seen. For the two groups combined,
the mean number of steps walked per ‘walking’ day for
the study increased from 3920 (SD 2441) per day during
the first week of the walking program (Week 7) to 6683
(SD 3403) per day during the final week of the program
(Week 18).
Differences between groups
No significant differences were found between groups
for the main outcome variables at any assessment week.
Therefore, data from both groups were combined for
the rest of the analyses. The only missing data were for
weight and body mass index (BMI) for one person in
Week 12, and for weight and BMI (n = 2), blood pres-
sure (n = 2), post-SPS WOMAC pain (n = 3) and SPS
(n = 3) at Week 18. Changes in outcome variables
between Week 6 and Week 24 are shown in Tables 3
and 4. Changes from baseline to Week 6 (GS supple-
mentation only) and from Week 6 to Week 24 (onset of
walking program to end of follow-up) are described
below. We chose to focus on Weeks 6 to 24 because,
from a public health point of view, it is important to
ascertain whether any effects are maintained after the
end of the program.
Changes between baseline and Week 6 (GS
supplementation only)
Although instructed not to increase their physical activ-
ity, from baseline to the Week 6 assessment, participants
significantly increased their median weekly minutes of
physical activity (Table 3). There were also significant
improvements (decreases) in SPS times and WOMAC
stiffness and physical function scores although
WOMAC pain scores did not change significantly
(Table 3). Scores on the Arthritis Self-Efficacy Scale
pain and ‘other symptom’ subscales and on the Barriers
to Physical Activity Scale also improved significantly
(Table 4).
Changes between Week 6 and Week 24
Between the start of the walking program (Week 6) and
the end of the follow-up period (Week 24), there were
significant improvements in participants’ weekly median
minutes of physical activity, in SPS test times and in all
WOMAC scores except stiffness scores (Table 3). How-
ever, there was a trend for improvement in stiffness
(P = 0.06). Significant improvements were also seen in
self-efficacy towards managing arthritis pain and ‘other
symptoms’, in physical activity self-regulation, and in the
number of perceived barriers to physical activity (Table
4). There were also trends for improvements in self-effi-
cacy towards managing arthritis-related functioning (P =
0.06), in self-efficacy towards physical activity (P = 0.07)
and in symptoms of anxiety and depression (P = 0.08).
Discussion
The main aims of this feasibility study were to evaluate
the combined effects of a progressive walking program
and GS intake on symptoms of OA and on physical
activity participation in people with hip and knee OA,
and to compare the effectiveness of two frequencies
(three and five days per week) and three steps levels
(1500, 3000 and 6000 steps) of walking. Thirty-six parti-
cipants were given GS for 18 weeks of the study. After
Table 2 Baseline demographic characteristics of
participants who completed the study
3-day walking
group
5-day walking
group
Total
n = 13 n = 15 n = 28
n (%) n (%) n (%)
Sex
Men 6 (46) 5 (33) 11 (39)
Women 7 (54) 10 (67) 17 (61)
Age (years)
40-59 4 (31) 7 (47) 11 (39)
60-75 9 (69) 8 (53) 17 (61)
BMI (kg/m
2)
<25 3 (23) 3 (20) 6 (21)
>25 10 (77) 12 (80) 22 (79)
Marital status
Married or common-law
relationship
9 (69) 9 (60) 18 (64)
Single 4 (31) 6 (40) 10 (36)
Highest educational level
achieved
High school degree or
less
5 (39) 6 (40) 11 (39)
Schooling beyond high
school
8 (61) 9 (60) 17 (61)
Current employment
status
Employed 7 (54) 6 (40) 13 (46)
Not employed 6 (46) 9 (60) 15 (54)
Main lifetime occupation
Manager or professional 8 (61) 4 (27) 12 (43)
Other 5 (39) 11 (73) 16 (57)
Note: No significant differences were found between groups for any
demographic variable (P > 0.05). BMI = body mass index.
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Stepping Out walking program and were randomised to
walk three or five days per week.
For the first six weeks, before the introduction of
Stepping Out, daily GS supplementation was found to
be effective in alleviating symptoms of hip and knee
OA. Stiffness and physical function, both measured with
WOMAC subscales, improved significantly (median
scores improved by 30% and 9%, respectively) although
pain, also measured with the WOMAC, did not. Objec-
tively-measured physical function also improved
significantly, by 13%. It is possible that these changes
were due to increases in physical activity in this period,
even though participants were asked to not change their
physical activity during this time. The improvements
partially support those from previous randomised con-
trolled trials. In these trials [23,24,52], improvements
were significantly greater for the groups assigned to
receive GS than for the groups assigned to receive pla-
cebos or alternative therapies. In a three-year trial,
Reginster and colleagues [24] found that among patients
with knee OA, WOMAC index scores improved 24%
Figure 3 Compliance with the Stepping Out program. (a) The percentage of participants who complied with the number of ‘walking’ days
per week of the walking program (Weeks 7 to 18 of the study). (b) Mean number of steps walked each ‘walking’ day during the 12-week
Stepping Out program (Weeks 7 to 18 of the study).
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function scores improved by 22%. Scores on the
WOMAC pain scale also improved, by 19%. In a three-
year trial by Pavelka and colleagues [23], patients with
knee OA who took GS experienced improvements in
pain and physical function of 20 to 25%. In a six-month
trial [52], patients with knee OA who were assigned to a
GS group had improvements in WOMAC index scores
of 12% and physical function scores of 13%. In other
trials [27,28,53], however, no significant improvements
with glucosamine supplementation were found. Differ-
ences in findings between studies can be explained in
part by the participant characteristics of each sample. In
the studies that found no improvements, participants
tended to have mild symptoms of OA at baseline. In the
current study and in other studies that found significant
improvements with GS, participants tended to have
moderate to moderately-high levels of symptoms (i.e.,
median scores above the median point in the scale) at
baseline. Other differences between studies include the
GS preparation used. The bioavailability of GS products
can affect the rate that the ingested GS reaches the tar-
g e tt i s s u et oe v o k em e t a b o l i cc h a n g e si nt h ea r t i c u l a r
cartilage [53]. This is the fir s tt i m et h a tt h eb e n e f i t so f
GS have been shown in a relatively short six-week
period.
The major finding of the current study was that being
encouraged to walk five days a week was not more
effective than being encouraged to walk three days, in
terms of increasing time spent in physical activities,
reducing pain and stiffness, increasing physical function,
and improving most other measures used in the study.
Table 3 Median scores and interquartile ranges for the main study outcomes
Week
0 6 12 18 24 6-24
Physical activity (min/week) 25
th 20.00 30.00 150.00 197.50 120.00 z 2.88
Median 55.00 100.00
a 225.00
b 352.50
c 190.00
d P <0.001
75
th 108.75 221.25 360.00 555.00 405.00 r 0.38
Physical function
Self-paced step test (seconds)
25
th 92.50 75.00 68.25 60.50 58.50 z -4.62
Median 104.00 90.50
a 79.50
b 73.50
c 70.00
d P <0.001
75
th 129.75 102.50 90.25 81.50 75.75 r 0.62
WOMAC measures
Arthritis pain 25
th 11.00 8.00 5.00 5.25 3.25 z -2.61
Median 15.50 15.00 12.50
b 12.00 9.00 P 0.01
75
th 24.75 24.75 19.00 19.00 14.00 r 0.35
Stiffness 25
th 7.25 3.50 3.25 4.00 3.25 z -1.87
Median 10.00 7.00
a 7.00 5.50 5.00 P 0.06
75
th 14.00 12.00 11.00 10.75 9.50 r 0.25
Physical function 25
th 44.25 26.50 13.00 12.00 15.75 z -3.11
Median 63.50 58.00
a 36.50
b 33.00 35.00 P <0.001
75
th 86.50 78.25 80.50 60.50 57.00 r 0.42
Pain after step test 25
th 9.25 6.25 1.50 1.88 0.25 z -3.11
Median 15.00 11.50 7.50
b 8.50 4.50 P <0.001
75
th 24.75 22.00 16.00 15.00 13.25 r 0.42
Total index 25
th 61.50 36.50 29.00 23.13 23.50 z -2.95
Median 89.50 77.50
a 53.00
b 48.00 51.50 P <0.001
75
th 123.75 119.00 111.50 85.25 80.00 r 0.39
Note. Z scores, P-values and effect sizes (r) for changes between Weeks 6 and 24 are shown in the right hand column.
a Week 6 significantly different from Week 0.
b Week 12 significantly different from Week 6.
c Week 18 significantly different from Week 12.
d Week 24 significantly different from Week 18.
r = Effect size; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
Ng et al. Arthritis Research & Therapy 2010, 12:R25
http://arthritis-research.com/content/12/1/R25
Page 10 of 15These findings are not surprising given that at each fol-
low up the three-day and five-day walking groups did
not differ significantly in the mean number of days actu-
ally walked per week, the mean number of daily steps
walked on each walking day as measured with a ped-
ometer or their weekly minutes of physical activity as
measured by questionnaire. On average, participants in
the three-day walking group walked three days per week
and participants in the five-day walking group walked
slightly less than four days per week, suggesting that it
may be difficult to get people with hip or knee OA to
walk more than three to four days per week. Another
important finding was that increasing the number of
steps per walking day from 1500 to 3000 steps per day,
in conjunction with GS intake, resulted in a 125%
increase in minutes of physical activity, a 17% reduction
Table 4 Median scores, interquartile range for secondary outcome variables
Week
0 6 12 18 24 6-24
Arthritis self-efficacy measures
Pain 25
th 45.00 53.50 58.50 60.50 70.00 z 2.64
Median 55.00 69.00
a 72.00 71.00 80.00
d P 0.01
75
th 72.00 75.50 86.00 90.00 91.50 r 0.35
Function 25
th 58.89 68.61 72.50 74.17 73.61 z 1.91
Median 74.44 79.44 86.67 88.33 88.89 P 0.06
75
th 89.44 89.72 94.72 92.22 94.17 r 0.26
Other symptoms 25
th 43.75 57.08 70.42 73.33 78.75 z -2.96
Median 61.67 68.33
a 78.33
b 83.33 85.83
d P <0.001
75
th 80.00 86.25 87.92 89.58 90.00 r 0.40
Correlates of physical activity measures
Self-regulation 25
th 23.25 19.50 34.00 33.38 30.75 z 3.69
Median 30.00 27.00 38.00
b 39.00 39.00 P <0.001
75
th 34.00 36.50 45.00 48.25 47.25 r 0.49
Self-efficacy 25
th 2.40 2.40 2.65 2.80 2.45 z 1.79
Median 2.80 3.00 3.10
b 3.20 3.30 P 0.07
75
th 3.20 3.35 3.55 3.60 3.75 r 0.24
Benefits 25
th 53.00 53.25 54.25 53.00 53.00 z -0.69
Median 56.00 56.00 57.00 56.00 54.50 P 0.49
75
th 62.50 63.00 65.00 64.00 64.25 r 0.09
Barriers 25
th 0.87 0.78 0.62 0.48 0.48 z -2.57
Median 1.48 1.04
a 1.02 0.86 0.98 P 0.01
75
th 2.03 1.63 1.46 1.55 1.47 r 0.34
Anxiety and depression (Goldberg) 25
th 4.25 1.25 2.00 2.00 1.00 z -1.73
Median 6.00 5.00 4.00 5.00 3.00 P 0.08
75
th 8.75 7.75 5.75 6.00 5.75 r 0.23
Weight (kg) 25
th 69.25 69.88 72.00 69.38 69.00 z -1.57
Median 79.50 80.00 81.00
b 79.25
c 79.50
d P 0.11
75
th 95.50 97.00 94.00 89.13 91.75 r 0.21
Note. Z scores, P-values and effect sizes (r) for changes between Weeks 6 and 24 are shown in the right hand column.
a Week 6 significantly different from Week 0.
b Week 12 significantly different from Week 6.
d Week 24 significantly different from Week 18.
r = Effect size.
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measured subjectively using the WOMAC (a 37% reduc-
tion in scores) and objectively using the SPS test (a 12%
decrease in time). When the walking step level was
increased from 3000 to 6000 steps a day, the primary
changes were a 57% increase in physical activity partici-
pation and an 8% improvement in objectively-measured
physical function. During the six-week follow up, min-
utes per week of physical activity decreased 46%, but
physical function, measured objectively, continued to
improve significantly, by 5%. These results suggest that
increasing walking by 3000 steps (about 30 minutes) on
at least three days per week can significantly reduce
pain and increase physical function in people with hip
or knee OA and that increasing walking from 3000
steps to 6000 steps on each walking day may offer addi-
tional significant improvements in physical function
only. In short, more benefit comes from increasing
walking by 3000 than from increasing walking by
another 3000 steps to 6000 steps.
The improvements in WOMAC pain and physical
function are consistent with those reported for rando-
mised controlled trials [14,15,44,54,55]. Kovar and col-
leagues [14] examined the effectiveness of an eight-week
supervised walking and patient education program for
102 participants with knee OA. Participants who
received the program exhibited a significant 27%
decrease in arthritis pain and a non-significant 39%
improvement in physical function. Similar results were
reported by Evcik and Sonel [54] for a three-month ran-
domised controlled trial with 90 participants with knee
OA. Participants in a walking group had significant
improvements ranging from 51% to 55% on the
WOMAC pain subscale and of 57% on the WOMAC
physical function subscale, compared with controls. In
the most recent study, 34 older adults with knee OA
were randomised to receive a pedometer-based walking
program with arthritis self-management education or
the education only [55]. Participants who received the
walking program had an improvement of 10% in pain
while the education-only participants reported no
improvement in pain. Differences between groups were
not statistically significant, possibly due to a lack of
power to detect differences because of the small sample
size.
Differences in effects among studies are likely to be
d u et od i f f e r e n c e si nan u m b e ro ff a c t o r s ,i n c l u d i n g
sample size; eligibility criteria, most notably the criteria
for exclusion based on baseline physical activity levels
and on measures used to determine OA status; length
of the intervention period; the physical activity prescrip-
tion; the attention from and contact with intervention
staff; the mode of intervention delivery; the type of ‘res-
cue medications’ allowed during the trial; and the choice
of outcome measures. Compared with other studies, the
current study was short (18 weeks) and included a small
sample. However, it was a feasibility designed to inform
al a r g e rs t u d y .I np r e v i o u ss tudies, protocols ranged
from supervised exercise in a hospital [14] to unsuper-
vised exercise with weekly phone calls [54]. Some
included both supervised and unsupervised exercise
[15]. Some studies prescribed a mix of aerobic and
strength training exercises [15,56,57], and others pre-
scribed just aerobic activity [22,55]. In the current study,
the exercise program was unsupervised walking and
contact time with the participants was minimal, in order
to test the effectiveness of a program that could be
widely disseminated. Another difference was that in the
current study, strict eligibility criteria were used to guar-
antee that only OA sufferers most in need of a physical
activity program (i.e., those who were engaging in no or
low levels of physical activity) were included. Other stu-
dies did not have exclusion criteria based on physical
activity [54,55]. Participants in the current study were
allowed rescue analgesia as needed while some previous
studies limited these to a maximum dose of 4000 mg
per day of paracetamol [27,53]. The highest dosage of
rescue analgesia recorded by participants in our study
was 2000 mg per day of paracetamol, which was taken
by 63% (n = 12) of those who took rescue medications.
Strengths
This study was the first to look at the effectiveness of
different frequencies and step levels of walking in com-
bination with GS for relieving symptoms of OA.
Although the study included only a small sample, the
findings provide preliminary evidence on the number of
walking steps needed to relieve OA symptoms and on
the effects of different step levels on OA symptoms.
Importantly, physical function was assessed with the
SPS test, an objective measure, to verify any improve-
ments found in physical function scores on the
WOMAC, and walking behaviour was measured objec-
tively with pedometers. Other instruments used in the
study were also validated measures commonly used in
the physical activity field. Another strength was that
behaviour change theory and the empirical literature
were used to develop the intervention strategies and
content. Previous studies have indicated that programs
designed to impact self-efficacy can have beneficial
effects for individuals with OA [57-59], and thus strate-
gies were developed to positively impact self-efficacy in
this study. For example, a pedometer was provided as a
self-monitoring and motivational tool, and monitoring
step counts made it possible to objectively assess the
amount of walking achieved by each participant. Record-
ing the number of steps on weekly log sheets provided
important information on participants’ progress and
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vious study [55] has used pedometers to increase physi-
cal activity among individuals with OA. Hence, this
feasibility study can help inform future research examin-
ing the use of pedometers for increasing physical activity
among individuals with knee or hip OA. Most studies
have looked at older (65+ years) adults with OA, but
this feasibility study included younger participants aged
40+ years, making the findings and the self-directed
intervention relevant to working adults. A final strength
was that the program was home-based and unsuper-
vised, to accommodate the schedules, symptoms and
walking ability of different participants. This made the
program easier to integrate into individuals’ lifestyles
than group-based activities. Anecdotally, several partici-
pants indicated that they would not have been able to
follow the program if it had involved regular attendance
at a class.
Limitations
The main limitation of the current study was the small
sample size. Difficulties with recruitment, as well as loss
to follow up, resulted in a small analysis sample. Some
of the loss to follow up was attributable to pre-existing
conditions that aggravated symptoms during the walking
program. However, two participants who dropped out
reported that their physicians advised against walking.
Also of note is that it is likely that a number of analyses
lacked power to detect differences between the two
walking groups. In addition, participants in the two
groups reported walking approximately the same num-
ber of days per week and spending similar minutes per
week in physical activities, making group differences in
the other outcome measures unlikely. Another limita-
tion was the use of self-report data. Although some stu-
dies use x-rays to assess changes in OA progression,
this study was too short to expect to see changes with
x-rays. Therefore, the primary outcome measure was the
WOMAC, which has been validated and is widely used
to examine the effects of exercise on OA symptoms
[34,35]. It should also be noted that most previous stu-
dies measured joint space narrowing to assess the effec-
tiveness of GS and exercise for OA sufferers [23,24,28].
This was not measured in the current study due to the
short intervention period of 18 weeks. We cannot,
therefore, conclude that a combination of walking and
GS supplementation will slow down joint space narrow-
ing, even though there was relief of OA symptoms.
Given that previous research has already shown that
exercise is beneficial for individuals with OA [60-63], the
main aim of the current study was to compare the effec-
tiveness of two walking programs in combination with
GS, rather than to compare walking to no walking.
Therefore, although a larger sample size would have
allowed for the inclusion of a no-walking control group,
the inclusion of such a control group was not essential to
meet the main aim. Without a placebo control, however,
the study was unable to determine the effects of GS com-
pared with placebo during the first six weeks of the inter-
vention and the effects of the walking program without
the use of GS during the remaining weeks. Furthermore,
the assessor and main analyst (NTMN) was not blinded
to group allocation and conducted the randomisation
process before baseline, which may have contributed to
ascertainment or performance biases. The current study
used a per-protocol analysis but an intent-to-treat analy-
sis should be used for a future study with a larger sample
size. Another minor limitation was that the weather may
have been a potential confounder. However, participants
continued to walk consistently throughout the 18-week
walking program and six-week follow up. Finally, it was
not possible to obtain radiographic evidence from all the
participants to confirm diagnosis and severity of their
OA. Participants who were unable to provide radio-
graphic evidence obtained a letter of diagnosis from their
physician, but severity of the disease was not confirmed.
However, from WOMAC scores obtained at baseline,
participants were found to have, on average, moderate
symptoms of knee or hip OA.
Conclusions
Although the study included a small sample, the findings
provide preliminary evidence that OA sufferers can
obtain health-related benefits from the combination of
GS and walking. Walking 3000 steps per day for exercise,
in bouts of at least 1500 steps each, on at least three days
per week, provided these benefits. This amount of walk-
ing is less than current physical activity recommenda-
tions for the general population, but follows the
recommendations for people with arthritis [19]. The
study also provides support for the acceptability of GS in
conjunction with a home-based walking program for
people with OA, as participants were willing to comply
with taking the glucosamine twice daily, wearing a ped-
ometer, completing log sheets, walking three days per
week and progressively increasing their steps per ‘walk-
ing’ day. With positive results, there is a need now to
conduct a larger placebo-controlled trial to strengthen
the findings and establish definitive data on the efficacy
of the Stepping Out program. If the benefits of this pro-
gram are confirmed, it could be promoted to increase
physical activity among people with hip or knee OA.
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